SCHEMBL2536283

SCHEMBL2536283

O=C1c2ccccc2C(=O)N1CCc1c[nH]c2ccc(OCc3ccccc3)cc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.67
▸ MAPT P10636 6/20 0.66
▸ MEN1 O00255 5/20 0.66
▸ KMT2A Q03164 5/20 0.66
▸ ALDH1A1 P00352 1/20 0.66
▸ TRPM8 Q7Z2W7 2/20 0.65
▸ KDM4E B2RXH2 1/20 0.65
▸ LMNA P02545 3/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ LTA4H P09960 3/20 0.64
▸ PLA2G2A P14555 3/20 0.64
▸ NPC1 O15118 2/20 0.61
▸ RAB9A P51151 2/20 0.61
▸ HTR1D P28221 5/20 0.61
▸ SLC6A4 P31645 1/20 0.59
▸ POLB P06746 1/20 0.58
▸ HTR1A P08908 2/20 0.56
▸ HTR1B P28222 2/20 0.56
▸ HTT P42858 1/20 0.55
▸ TP53 P04637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31660992 1.00 GAA (0.67) GAAMAPTMEN1KMT2AALDH1A1
SCHEMBL2534045 0.87 MAPT (0.69) GAAMAPTMEN1KMT2AALDH1A1
SCHEMBL2823989 0.85 TRPM8 (0.62) MAPTMEN1KMT2ATRPM8KDM4E
SCHEMBL5148291 0.85 MAPT (0.70) GAAMAPTMEN1KMT2AALDH1A1
SCHEMBL8229566 0.84 MAPT (0.87) GAAMAPTMEN1KMT2AALDH1A1
SCHEMBL2539868 0.84 MAPT (0.62) GAAMAPTMEN1KMT2AALDH1A1
SCHEMBL5148298 0.81 MAPT (0.68) GAAMAPTMEN1KMT2AALDH1A1
SCHEMBL26826151 0.81 MAPT (0.65) GAAMAPTMEN1KMT2AALDH1A1
SCHEMBL8691287 0.81 HTR1A (0.64) GAAMAPTMEN1KMT2AALDH1A1
SCHEMBL8880777 0.80 HTR1A (0.66) GAAMAPTMEN1KMT2ATRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1859798-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2015-12-30 — — EP disclosed
US-8044090-B2 N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor ELI LILLY (US) 2011-10-25 — — US disclosed
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2009-12-10 — — US disclosed
EP-1859798-A1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2007-11-28 — — EP disclosed
EP-1379239-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2007-09-12 — — EP disclosed
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2007-05-03 — — US disclosed
US-7157488-B2 N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor ELI LILLY AND COMPANY (US) 2007-01-02 — — US disclosed
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US disclosed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP disclosed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO disclosed
US-6197975-B1 7-AZABICYCLO(2.2.1)HEPTANE-7-CARBONYL-SUBSTITUTED 2-PHENYLINDOLE DERIVATIVES; SEXUAL DISORDERS; ANTICARCINOGENIC AGENTS MERCK & CO. , INC. 2001-03-06 — — US disclosed
EP-0882040-A4 ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE MERCK & CO INC (US) 1999-02-10 — — EP disclosed
EP-0882040-A1 ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE Merck & Co., Inc. (US) 1998-12-09 — — EP disclosed
WO-1997021707-A1 ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE MERCK & CO., INC. (US) 1997-06-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B GAA 4200/4885MAPT 3701/4885MEN1 1889/4885
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B GAA 4200/4885MAPT 3701/4885MEN1 1889/4885
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B GAA 4200/4885MAPT 3701/4885MEN1 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback